now this really sux, page-21

A comment from our Mr Wolgen not so long ago...

"A pricing study is underway in Europe to
explore the range of pricing in ODD and improving the quality of life in
patients that are house-bound. We hope to have these results by November this
year."

So they are doing marketing studies even though its not approved for Europe yet.....either smart business or very confident that it will get the ability to market it in Europe!

And this...

"CEO Philippe Wolgen
We will inform the market of our plans to manufacture on large scale shortly,
and this will be part of our commercial direction."

And this question ...

"corporatefile.com.au
Cash reserves at the end of June 2009 were $37.5 million. Do you have
sufficient funding to complete the Phase III trials of EPP in Europe and US and
apply for regulatory approval for afamelanotide? Is it necessary to raise capital
in the short-term?
CEO Philippe Wolgen
We have ample cash available to complete this program and are fully funded
for the filing for marketing authorisation for afamelanotide."

AMPLE CASH FOR PHASE 3 AND MARKETING AUTH!

Not many can claim that during the GFC without a rights issue or diluting shares more by selling to second parties.

I think CUV is in a great position. But Im invested in this, so Im not worried if announcements are delayed a month or 2. :)